Clinical Trial Update: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study [Phase 3]

View source ↗

Summary

PDIGREE is a Phase 3 trial evaluating nivolumab plus ipilimumab followed by nivolumab with or without cabozantinib in advanced renal cell carcinoma; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Cabometyx (cabozantinib) (cabozantinib)
• Opdivo (nivolumab) (nivolumab)
• Yervoy (Ipilimumab) (Ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 3 | Status: ACTIVE_NOT_RECRUITING